Abagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Abagovomab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Abagovomab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Abagovomab. |
| Estrone | Estrone may increase the thrombogenic activities of Abagovomab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Abagovomab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Abagovomab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Abagovomab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Abagovomab. |
| Estriol | Estriol may increase the thrombogenic activities of Abagovomab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Abagovomab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Abagovomab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Abagovomab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Abagovomab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Abagovomab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Abagovomab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Abagovomab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Abagovomab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Abagovomab. |
| Equol | Equol may increase the thrombogenic activities of Abagovomab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Abagovomab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Abagovomab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Abagovomab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Abagovomab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Abagovomab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Abagovomab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Abagovomab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Abagovomab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Abagovomab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Abagovomab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Abagovomab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Abagovomab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Abagovomab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Abagovomab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Abagovomab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Abagovomab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Abagovomab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Abagovomab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Abagovomab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Abagovomab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Abagovomab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Abagovomab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Abagovomab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Abagovomab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Abagovomab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Abagovomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abagovomab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Abagovomab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Abagovomab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abagovomab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Abagovomab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Abagovomab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Abagovomab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Abagovomab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Abagovomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Abagovomab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Abagovomab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Abagovomab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Abagovomab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Abagovomab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Abagovomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Abagovomab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Abagovomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Abagovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Abagovomab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Abagovomab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Abagovomab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Abagovomab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Abagovomab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Abagovomab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Abagovomab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Abagovomab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Abagovomab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Abagovomab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Abagovomab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Abagovomab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Abagovomab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Abagovomab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Abagovomab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Abagovomab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Abagovomab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Abagovomab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Abagovomab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Abagovomab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Abagovomab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Abagovomab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Abagovomab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Abagovomab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Abagovomab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Abagovomab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Abagovomab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Abagovomab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Abagovomab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Abagovomab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Abagovomab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Abagovomab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Abagovomab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Abagovomab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Abagovomab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Abagovomab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Abagovomab. |